Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M. Gansler as Executive Vice President, Chief People Officer (CPO).
“Supported by our highly positive SER-109 Phase 3 results, we are expanding our capabilities and strengthening the Seres team as we move towards what we expect to be the first-ever FDA-approved microbiome therapy. We have taken meaningful steps to prepare for our anticipated growth into a commercial-stage enterprise. Earlier this year, we appointed Lisa von Moltke, M.D., FCP, as Seres’ Chief Medical Officer and Terri Young, Ph.D., R.Ph., as Chief Commercial and Strategy Officer, and we are pleased to now add two additional highly accomplished professionals to Seres’ executive team. Dave’s experience successfully leading the manufacturing of prominent pharmaceuticals, including Keytruda®, will be vital as we look ahead to the expected commercialization of SER-109. Jayne has held critical roles building global biopharmaceutical companies and this experience will be central to attracting top talent to Seres, an effort which is well underway. I am honored to work with such a talented and diverse team,” said Eric D. Shaff, President and Chief Executive Officer of Seres.
Mr. Shaff continued: “I also want to take this opportunity to express our deep appreciation to John Aunins, Ph.D. John has led Seres’ manufacturing efforts since soon after the company was formed, and he has been critical in building our field-leading CMC capabilities in this new therapeutic modality. We are pleased that John will continue to support Seres in a Senior Advisor capacity.”
Dr. Ege brings to the role of CTO more than 15 years of experience in the pharmaceutical industry with a focus on manufacturing and developing vaccines and biologics. He joins Seres after an extensive career at Merck, where he worked on a number of breakthrough, novel products with complex manufacturing. Dr. Ege joined Merck in 2003 and served in a variety of technical and leadership roles in R&D and manufacturing. He was most recently Global Lead for Digital Strategy in Merck’s Manufacturing Division, in charge of driving business optimization, leading digital innovation, and helping advance products to market. Dr. Ege also held roles as Executive Director of Vaccines & Biologics Manufacturing and Head of Commercial Manufacturing Operations during his time at Merck. Dr. Ege graduated summa cum laude from Princeton with a BSE in chemical engineering and earned his Ph.D. in chemical engineering from the University of Pennsylvania.
Ms. Gansler brings to the newly created role of CPO more than 25 years of experience leading global human resources organizations in the biotechnology, pharmaceutical and medical device industries. Prior to joining Seres, Ms. Gansler was Senior Vice President, Head of Human Resources at ARIAD Pharmaceuticals and served as a key leader during a time of significant change that included the sale and integration of ARIAD with Takeda Pharmaceuticals. She served as Senior Vice President, Global Head of Human Resources for Genzyme, a Sanofi Company, following Sanofi’s acquisition of Genzyme Corporation and led the integration and rebuilding of the HR strategy for Genzyme, a Sanofi Company. Ms. Gansler’s strong business acumen and relationship-building skills helped lead Genzyme to be recognized by Fortune Magazine as one of the 100 Best Companies to Work For. Prior to joining Genzyme, Jayne began her career at Johnson & Johnson where she held various senior human resources roles. She earned her B.A. in human resource management and labor relations from the University of Massachusetts, Amherst.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.